MA54821A - Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques - Google Patents
Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiquesInfo
- Publication number
- MA54821A MA54821A MA054821A MA54821A MA54821A MA 54821 A MA54821 A MA 54821A MA 054821 A MA054821 A MA 054821A MA 54821 A MA54821 A MA 54821A MA 54821 A MA54821 A MA 54821A
- Authority
- MA
- Morocco
- Prior art keywords
- survival
- exposure
- response
- methods
- protection against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796728P | 2019-01-25 | 2019-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54821A true MA54821A (fr) | 2021-12-01 |
Family
ID=69740564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054821A MA54821A (fr) | 2019-01-25 | 2020-01-24 | Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237872A1 (enExample) |
| EP (1) | EP3914281A1 (enExample) |
| JP (1) | JP7664163B2 (enExample) |
| KR (1) | KR20210119469A (enExample) |
| CN (1) | CN113660943A (enExample) |
| AU (1) | AU2020210869A1 (enExample) |
| CA (1) | CA3127458A1 (enExample) |
| IL (1) | IL285092A (enExample) |
| MA (1) | MA54821A (enExample) |
| MX (1) | MX2021008928A (enExample) |
| WO (1) | WO2020154637A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7481252B2 (ja) | 2017-07-26 | 2024-05-10 | ヤンセン ファーマシューティカ エヌ．ベー． | 標的放射線治療誘発性血管完全性を保護する方法 |
| MA54820A (fr) * | 2019-01-25 | 2021-12-01 | Janssen Pharmaceutica Nv | Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques |
| CN118660955A (zh) * | 2021-10-01 | 2024-09-17 | 詹森药业有限公司 | 增加祖细胞生产的方法 |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU680422B2 (en) | 1992-06-11 | 1997-07-31 | Alkermes Controlled Therapeutics, Inc. | Erythropoietin drug delivery system |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| RS20060141A (sr) | 2003-08-28 | 2008-08-07 | Ortho-Mcneil Pharmaceutical Inc., | Peptidi i jedinjenja koja se vežu za receptor |
| US7723295B2 (en) | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| US20060210542A1 (en) | 2004-08-16 | 2006-09-21 | Yurkow Edward J | Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| PT1984014E (pt) | 2006-02-14 | 2014-11-13 | Janssen Pharmaceutica Nv | Utilização de compostos de péptidos tpo e composições farmacêuticas no tratamento da anemia |
| KR20110015448A (ko) | 2008-06-03 | 2011-02-15 | 얀센 파마슈티카 엔.브이. | 암 치료와 관련된 혈액 질환을 예방하기 위한 ｔｐｏ 모방 펩티드 |
| BR112014028094B1 (pt) * | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| US20140051631A1 (en) * | 2012-08-17 | 2014-02-20 | Francoise Porteu | Pharmaceutical composition comprising tpo or an agonist of the tpo receptor |
| JP6150374B2 (ja) * | 2012-11-15 | 2017-06-21 | 国立大学法人弘前大学 | 放射線被ばく治療剤及び放射線被ばく治療方法 |
-
2020
- 2020-01-24 US US16/752,559 patent/US20200237872A1/en not_active Abandoned
- 2020-01-24 CA CA3127458A patent/CA3127458A1/en active Pending
- 2020-01-24 WO PCT/US2020/015015 patent/WO2020154637A1/en not_active Ceased
- 2020-01-24 AU AU2020210869A patent/AU2020210869A1/en not_active Abandoned
- 2020-01-24 JP JP2021542516A patent/JP7664163B2/ja active Active
- 2020-01-24 EP EP20708763.6A patent/EP3914281A1/en not_active Withdrawn
- 2020-01-24 MX MX2021008928A patent/MX2021008928A/es unknown
- 2020-01-24 MA MA054821A patent/MA54821A/fr unknown
- 2020-01-24 KR KR1020217026699A patent/KR20210119469A/ko not_active Ceased
- 2020-01-24 CN CN202080023563.6A patent/CN113660943A/zh active Pending
-
2021
- 2021-07-23 IL IL285092A patent/IL285092A/en unknown
-
2022
- 2022-02-18 US US17/651,675 patent/US20220168392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220168392A1 (en) | 2022-06-02 |
| US20200237872A1 (en) | 2020-07-30 |
| KR20210119469A (ko) | 2021-10-05 |
| JP7664163B2 (ja) | 2025-04-17 |
| JP2022519196A (ja) | 2022-03-22 |
| IL285092A (en) | 2021-09-30 |
| MX2021008928A (es) | 2021-11-04 |
| WO2020154637A9 (en) | 2020-08-27 |
| WO2020154637A1 (en) | 2020-07-30 |
| CA3127458A1 (en) | 2020-07-30 |
| EP3914281A1 (en) | 2021-12-01 |
| AU2020210869A1 (en) | 2021-08-19 |
| CN113660943A (zh) | 2021-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3463381A4 (en) | NUCLEOTIDE DERIVATIVES AND METHOD FOR USE THEREOF | |
| UY35281A (es) | Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos | |
| EP3356381A4 (en) | DESIGN AND SYNTHESIS OF NUCLEOTIDES BASED ON NOVEL DISULFIDE COMPOUNDS AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | |
| EP3399956A4 (en) | COSMETIC COMPOSITIONS WITH CERAMIDES AND CHOLESTEROL | |
| EP3359167A4 (en) | METHOD AND COMPOSITIONS FOR INCREASING HUMAN SOMATIC CELL CORE TRANSFER EFFICIENCY BY REMOVING HISTON-H3-LYSINE TRIMETHYLATION AND DERIVING FROM HUMAN NT-ESC | |
| HUE054272T2 (hu) | Összetételek és módszerek az argináz-tevékenység gátlásához | |
| MA46959A (fr) | Cellules b modifiées et compositions et méthodes associées | |
| EP3342414A4 (en) | MEANS FOR IMPROVING ATP IN CELLS | |
| EP3471717A4 (en) | TREATMENT OF PLATE CELL CARCINOMAS WITH ERK INHIBITORS | |
| EP3436031A4 (en) | Novel RNA construct and method of use therefor for increasing the therapeutic effects of cytotoxic cells and stem cells | |
| FR3041114B1 (fr) | Articulation de lunettes et lunettes correspondantes | |
| EP3270941A4 (en) | COMPOSITIONS WITH SILYMARIN AND SULFOALKYL ETHERCYCLODEXTRIN AND METHOD OF USE THEREOF | |
| DK3086784T3 (da) | Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose | |
| EP4086351C0 (en) | VIRAL VECTORS FOR TREATING NEUROGENIC DETRUSOR HYPERACTIVITY | |
| EP3548617A4 (en) | OPTIMIZED LENTIVIRAL VECTOR FOR STEM CELL THERAPY OF HEMOGLOBINOPATHIA | |
| EP3417313A4 (en) | ACCIDENT COSTING | |
| DK4076461T3 (da) | Lumateperon til brug ved behandling af skizofreni | |
| PL3655013T3 (pl) | Ukierunkowanie na synaptogirynę-3 w leczeniu tauopatii | |
| EP3419656A4 (en) | NEOANTIGEN COMPOSITIONS AND METHODS FOR USE THEREOF IN IMMUNOOTHERAPY | |
| IT201900021687A1 (it) | Impianto e procedimento di trattamento di accumulatori esausti o dismessi. | |
| EP3731841A4 (en) | CRYOPERVATIVE COMPOSITIONS AND METHOD OF USING THEREOF | |
| EP3505568A4 (en) | IONIC COMPOSITION AND NETWORKED PRODUCT | |
| DK4043014T3 (da) | Farmaceutisk sammensætning indeholdende heterocyklidenacetamid-derivat til brug til behandling af tørre øjne | |
| BR112016028009A2 (pt) | métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos | |
| EP3509595A4 (en) | FORMULATIONS OF HYDROXYPYRIDONATE ACTINIDE / LANTHANID DECORPORATION AGENTS |